Abemaciclib
Sign in to save this workspacePrimary targets: CDK4_CYCLIN_D1, CDK4_CYCLIN_D3, CDK4_CYCLIN_D2, CDK6_CYCLIN_D1, CDK6_CYCLIN_D3, CDK6_CYCLIN_D2 · FDA status: FDA Approved
Selectivity scorecard
KISS
91.48
Gini
0.563
CATDS
0.008
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Abemaciclib. Strongest target: CDK4_CYCLIN_D3 at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CDK4_CYCLIN_D3 | 100.0% | 0.0% |
| 2 | DYRK3 | 100.0% | 0.0% |
| 3 | PIM3 | 100.0% | 0.0% |
| 4 | CAMK2A | 99.7% | 0.3% |
| 5 | CLK1 | 99.5% | 0.5% |
| 6 | CDK6_CYCLIN_D1 | 99.3% | 0.7% |
| 7 | CDK4_CYCLIN_D1 | 99.2% | 0.8% |
| 8 | CDK9_CYCLIN_T2 | 99.0% | 1.0% |
| 9 | DYRK1B | 98.9% | 1.1% |
| 10 | PIM1 | 98.8% | 1.2% |
| 11 | CDK6_CYCLIN_D3 | 98.7% | 1.3% |
| 12 | CAMK2B | 98.6% | 1.4% |
| 13 | CAMK2D | 98.6% | 1.4% |
| 14 | IRAK1 | 98.3% | 1.7% |
| 15 | HIPK2 | 98.2% | 1.8% |
| 16 | DYRK1_DYRK1A | 97.7% | 2.3% |
| 17 | CDK9_CYCLIN_T1 | 97.2% | 2.8% |
| 18 | GSK3A | 97.2% | 2.8% |
| 19 | DYRK2 | 97.1% | 2.9% |
| 20 | ERK7_MAPK15 | 96.7% | 3.3% |
Selectivity landscape
Where Abemaciclib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Abemaciclib.
Atlas insights for Abemaciclib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.873 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.854 |
| SRR12202498 | — | 0.835 |
| R247 | — | 0.833 |
| b6a7e87e-2674-4a48-a3c2-c8a9806762b5 | — | 0.832 |
Annotations
Sign in to read and post annotations.
Loading…